



# Farm To Shelf, Low-Cost, High-Margin Medical Cannabis

Specifically helping veterans and first responders with PTSD, Allied Health leverages the most fertile and cost-effective land in South America together with world-class Canadian plant genetic technology to bring highly profitable medical cannabis to the global market.



## The future of global supply

Initial operations take advantage of the world's best growing conditions in South America, with low production costs and cannabis-friendly countries.



## Nano-technology driven products

Nano-based tech gives patients and consumers a predictable onset and duration of therapeutic effects without having to smoke any plant material.



## Advanced genetics propels production

Proprietary production methods to be based on Allied's impressive library of proven gene technology already acclimatized to the South American climate.




## Experienced Management Team

Corporate acumen, decades of cannabis growing & extraction proficiency, clinical healthcare & pharmaceutical experience, and regional agricultural expertise.

## Low-Cost, High-Margin Advantage at Scale

Cultivation Cap Ex Start Up Costs per/ft2



- Expected production costs 10-16x lower than competitors' in Canada\*
- Lower capex = higher potential ROI and ability to scale
- 10+M sq.ft of cultivation planned in Columbia alone
- Production forecast: ~85kgs in 2020 and ~420kgs in 2021

\* Canadian avg cost of production is \$1.52 CDN/gram based on competitor reports and disclosure documents; Allied's cost of production is anticipated at \$.10-.15/gram.



## Reaching & Filling a Rapidly Growing Market Need

- Products target specific receptors to provide therapeutic relief for veterans and first responders living with PTSD.
- Allied has secured access to NATO country veterans and first responders, including a massive patient base.

# South America Operations

- Fully licensed in Colombia under LOI: psycho-active, non-psychoactive, export & formulation licenses
- One of the largest owned, leased & optioned land packages in South America
- Team with plant science & cannabis production experience needed for South American climate
- Low variance temperatures year-round, rich fertile soils & abundant water supply
- Premium quality product with multiple harvests per year
- Low-cost, experienced, and large available work force

# Canada Operations

- Manufacture of hemp-derived CBD products from cost-effective, internationally sourced materials
- Distribution in Canada & into the United States
- Patented nano-tech provides the most dependable & healthiest consumption without loss of therapeutic benefits
- Final 20% of processing in Canada enables “Canadian-made products for Allied Veterans”
- British Columbia location leads the globe in strain development & production knowledge

## Milestones

### Completed

- Acquired a catalogue of 10+ CBD products - April 2019
- Falcon Ridge Acquisition (Canadian late-stage Licensed Producer with 50+ CBD product catalogue for sale in Canada and US) - May 2019
- MediColombias Acquisition (Colombian Licensed Producer) - May 2019
- Colombian National Ministry of Agriculture approval for seed evaluation - May 2019
- Purchase of Canadian property for extraction/processing - May 2019
- Natural Health products distributed for sale in US - June 2019

### 2019 Q3/4

- Initial planting for Columbian operations - Q3 2019
- Modular buildings for extraction and processing ready - Q3 2019
- Canadian extraction and processing capacity up and running - Q4 2019

## Capital Structure

SHARE COUNT (MILLIONS)	
Fully diluted*	Approx. 80
Warrants	n/a
Debt	0
Management, Founders, and Directors	48   60% of fully diluted
<b>Current Cash Position</b> <small>(April 2019)</small>	<b>Approx. \$0.40</b>

\*Includes estimated number of shares to be issued as consideration for completed transactions for licenses and equipment acquisition.

## Management Team

### Calum Hughes CEO, Founder, Director

15+ yrs experience in healthcare in a leadership role, including Director of 140-bed acute care hospital. Currently holds Adjunct Professor position at University of British Columbia in areas of Health Economics, Health Evaluation, and Canadian Health Systems. Has consulted for Canadian government within health sector, and for public sector in pharmaceutical industry.

### David Weinkauf CBD0, Director

25+ yrs in commercial real estate leasing, land development, and sales involving over \$3.0B in development, 10M ft2 in facilities, and 3000 acres of land. Involvement in building numerous private and public entities has included identifying unique opportunities, securing investment, and directing strategic development and growth.

### Anthony Zelen CCO, Director

20+ yrs finance, investor relations, and corporate development, occupying numerous board and executive positions. Venture capital arena activities have established a network of accredited investors, angel investors, and investment banking contacts throughout North America, Europe, and Asia.

### Jim Bullock COO, Director

10+ yrs in industrial-scale cannabis cultivation, genetics, compliance, and facility design. 10+ yrs in commercial agricultural management and consulting.